However, low expression of IL12B in the tumor samples of both the EGFRwt and EGFRmut LUAD patients was related to poor OS, and the overall living risks for EGFRmut LUAD patients was 2 times higher than that observed for the EGFRwt LUAD patients (HR = 0.688, 95% CI = 0.503–0.939, and p = 0.0186 for the high vs. low IL12B expression EGFRwt subgroup; HR = 0.318, 95% CI = 0.132–0.769, and p = 0.011 for the high vs. low IL12B expression EGFRmut subgroup; Fig. 4D). Here, IL12B is linked to neoplasm.